Home GenSight Biologics

GenSight Biologics

GenSight Biologics Reports Long-Term Positive Safety and Visual Acuity Results at Week 96 in Phase I/II Study of GS010 for the Treatment of Leber’s...

Sustained clinically significant improvement of visual acuity in LHON patients with less than 2 years of visual...